Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

HOOKIPA Pharma Inc. Announces Clinical Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA« (pembrolizumab) in patients with advanced head and neck cancers

09/15/2021 | 07:00am EDT

HOOKIPA Pharma Inc. announced it has entered into a clinical collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ., USA (known as MSD outside of the United States and Canada) to evaluate the combination of HB-200, a novel arenaviral immunotherapeutic, and Merck & Co., Inc., Kenilworth, NJ., USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) as first-line treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC). The collaboration has been initiated based on promising data from the ongoing HB-200 Phase 1/2 clinical trial (NCT04180215) in advanced HPV16+ cancers. As reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, 15 patients with metastatic head and neck cancers were eligible for the efficacy analysis, as of data cut-off. HB-201 monotherapy showed an 18% overall response rate and median progression-free survival of 3.45 months in heavily pretreated head and neck cancer patients, better than current 2nd-line treatment. In addition, preliminary data on HB-201/HB-202 therapy showed a disease control rate of 100% (4/4 patients). Importantly, the Phase 1 data on 38 evaluable patients showed that HB-200 therapy has a favorable safety profile in heavily pre-treated patients with HPV16+ cancers, underlining its potential as a monotherapy and in possible combination with checkpoint inhibitors. With a HB-200 program data read-out anticipated by Fourth Quarter 2021, HOOKIPA anticipates initiating a Phase 2 trial with HB-200 in combination with KEYTRUDA in 2022. Additional Phase 2 expansion cohorts are also planned to start in First Quarter 2022.


ę S&P Capital IQ 2021
All news about MERCK & CO., INC.
10/15MERCK : And Co. Gets European Medicines Agency's Positive Opinions on Pneumonia Vaccine, C..
MT
10/15MERCK : Receives Positive Opinions From European Medicines Agency on Pneumonia Vaccine, Ca..
MT
10/15Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
DJ
10/15MERCK : and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA« (pembrolizumab) Plus LEN..
BU
10/15MERCK : Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conj..
BU
10/15Merck Gets CHMP Positive Opinion for Vaxneuvance Vaccine
DJ
10/15MERCK : US FDA To Review Merck & Co.'s COVID-19 Antiviral Drug For Approval In Late Novemb..
MT
10/14MERCK : FDA to Review Merck's Emergency Use Authorization Request For Molnupiravir COVID-1..
MT
10/14MERCK : Nov 30th FDA Advisory Committee meeting to Discuss Merck & Ridgeback's COVID-19 An..
MT
10/14MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 042 M - -
Net income 2021 13 209 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 16,5x
Yield 2021 3,31%
Capitalization 198 B 198 B -
EV / Sales 2021 4,49x
EV / Sales 2022 3,98x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 78,33 $
Average target price 95,16 $
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-4.24%198 283
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657